Seattle biotech firm Silverback Therapeutics aims for $100M IPO

Seattle biotechnology company Silverback Therapeutics has filed preliminary plans to raise $100 million or more in an initial public offering.

The clinical-stage biopharmaceutical company, which has one product candidate in an early clinical trial targeting metastatic solid tumors, says its technology aims to “to create potent therapeutic molecules that can be systemically administered to patients, but that act only at the sites of disease, sparing healthy tissues from unwanted side effects.”